XenoTherapeutics
Founded Year
2016Stage
Unattributed | AliveTotal Raised
$700KLast Raised
$700K | 3 yrs agoAbout XenoTherapeutics
XenoTherapeutics is a medical device company whose product XenoSkin is a human tissue substitute is derived from genetically modified pigs and serves as a new solution for burn injuries.
XenoTherapeutics Headquarter Location
359 Newbury St
Boston, Massachusetts, 02115,
United States
617-939-7892
Expert Collections containing XenoTherapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
XenoTherapeutics is included in 2 Expert Collections, including Medical Devices.
Medical Devices
8,395 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,900 items
XenoTherapeutics Patents
XenoTherapeutics has filed 10 patents.
The 3 most popular patent topics include:
- Transplantation medicine
- Clusters of differentiation
- Immune system
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/22/2021 | 10/26/2021 | Immunology, Transcription factors, Immune system, Clusters of differentiation, Transplantation medicine | Grant |
Application Date | 4/22/2021 |
---|---|
Grant Date | 10/26/2021 |
Title | |
Related Topics | Immunology, Transcription factors, Immune system, Clusters of differentiation, Transplantation medicine |
Status | Grant |
Latest XenoTherapeutics News
Nov 7, 2020
From Pig to Patient: XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant; Evidence of Safety and Efficacy Allows for Accelerated Patient Enrollment From Pig to Patient: XenoTherapeutics Completes First Cohort of Patients in First US Clinical Trial of Live-Cell Xenotransplant; Evidence of Safety and Efficacy Allows for Accelerated Patient Enrollment Share Last updated Nov 5, 2020 BOSTON, MA, Nov. 05, 2020 (GLOBE NEWSWIRE) — XenoTherapeutics, a clinical-stage cell and gene therapy company engineering immune-compatible cells, tissues, and organs, has completed the first of two patient cohorts in the company’s Phase I clinical trial of Xeno-Skin™, a first-in-human, live-cell xenotransplant for the treatment of severe and extensive burn wounds. As a result, the U.S. Food and Drug Administration (FDA) has agreed to permit accelerated patient enrollment; patients may now enroll in the trial’s second cohort simultaneously. This first-in-human trial, conducted in partnership with the Massachusetts General Hospital, is expected to be completed by the end of 2020. More information is available at clinicaltrials.gov . “As an engineer and scientist, I’m trained to be skeptical and rely heavily on real data, and to prioritize facts above what we hope to see as a company. In this case, the evidence speaks for itself – there’s no doubt this works. Combine these results with our understanding of essential regulatory requirements specifically related to xenotransplantation, and our demonstrated capability in clinical grade manufacturing of xenotransplantation products, this seemingly small step has significant positive implications for patient care, for our field, and where we’re headed,” said XenoTherapeutics Corporation CEO Paul Holzer. “This affirms my enthusiasm for where our discoveries will go from here – very big things are coming soon.” Surgeries to implant Xeno-Skin™ were performed under the care of Dr. Jeremy Goverman (Principal Investigator) and Dr. John Schulz at the Massachusetts General Hospital (MGH) Sumner Redstone Burn Center. All patients who participated in the trial received surgical transplants of both live skin from a clinical-grade, genetically engineered porcine donor …
When was XenoTherapeutics founded?
XenoTherapeutics was founded in 2016.
Where is XenoTherapeutics's headquarters?
XenoTherapeutics's headquarters is located at 359 Newbury St, Boston.
What is XenoTherapeutics's latest funding round?
XenoTherapeutics's latest funding round is Unattributed.
How much did XenoTherapeutics raise?
XenoTherapeutics raised a total of $700K.
Who are the investors of XenoTherapeutics?
Investors of XenoTherapeutics include MassChallenge.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.